RESUMEN
Chronic kidney disease (CKD) commonly occurs with vitamin K (VK) deficiency and impaired bone mineralization. However, there are no data explaining the metabolism of endogenous VK and its role in bone mineralization in CKD. In this study, we measured serum levels of phylloquinone (VK1), menaquinone 4 and 7 (MK4, MK7), and VK-dependent proteins: osteocalcin, undercarboxylated osteocalcin (Glu-OC), and undercarboxylated matrix Gla protein (ucMGP). The carboxylated osteocalcin (Gla-OC), Glu-OC, and the expression of genes involved in VK cycle were determined in bone. The obtained results were juxtaposed with the bone mineral status of rats with CKD. The obtained results suggest that the reduced VK1 level observed in CKD rats may be caused by the accelerated conversion of VK1 to the form of menaquinones. The bone tissue possesses all enzymes, enabling the conversion of VK1 to menaquinones and VK recycling. However, in the course of CKD with hyperparathyroidism, the intensified osteoblastogenesis causes the generation of immature osteoblasts with impaired mineralization. The particular clinical significance seems to have a finding that serum osteocalcin and Glu-OC, commonly used biomarkers of VK deficiency, could be inappropriate in CKD conditions, whereas Gla-OC synthesized in bone appears to have an adverse impact on bone mineral status in this model.
Asunto(s)
Insuficiencia Renal Crónica , Deficiencia de Vitamina K , Animales , Biomarcadores , Huesos/metabolismo , Minerales/metabolismo , Osteocalcina , Ratas , Insuficiencia Renal Crónica/complicaciones , Vitamina K , Vitamina K 1 , Vitamina K 2 , Deficiencia de Vitamina K/etiologíaRESUMEN
Hyperemesis gravidarum (HG), severe nausea and vomiting in pregnancy, can lead to vitamin deficiencies. Little is known about HG-related vitamin K deficiency. We aimed to summarise available evidence on the occurrence of HG-related vitamin K deficiency and corresponding maternal and neonatal complications. A systematic review was conducted, searching Medline and EMBASE from inception to 12 November 2020. We identified 1564 articles, of which we included fifteen in this study: fourteen case reports (n 21 women) and one retrospective cohort study (n 109 women). Nine out of twenty-one women reported in case reports had a prolonged prothrombin time (PT). The cohort study measured PT in 39/109 women with HG, of whom 10/39 women (26 %) had prolonged PT. In total, 30-50 % women received vitamin K supplementation after vitamin K deficiency had been diagnosed. Four case reports (n 4 women) reported corresponding maternal complications, all consisting of coagulopathy-related haemorrhage. Nine case reports (n 16 neonates) reported corresponding neonatal complications including intracranial haemorrhage (n 2 neonates) and embryopathy (n 14 neonates), which consisted of Binder phenotype (n 14 neonates), chondrodysplasia punctata (n 9 neonates) and grey matter heterotopia (n 3 neonates). In conclusion, vitamin K deficiency and related complications occur among women with HG. In our systematic review, we were unable to assess the incidence rate.
Asunto(s)
Hiperemesis Gravídica , Deficiencia de Vitamina K , Embarazo , Humanos , Femenino , Masculino , Hiperemesis Gravídica/complicaciones , Hiperemesis Gravídica/diagnóstico , Estudios de Cohortes , Estudios Retrospectivos , Deficiencia de Vitamina K/etiología , Vitamina KRESUMEN
Coronavirus disease 2019 (Covid-19), caused by severe acute respiratory syndrome coronavirus (SARS-CoV)-2, exerts far-reaching effects on public health and socio-economic welfare. The majority of infected individuals have mild to moderate symptoms, but a significant proportion develops respiratory failure due to pneumonia. Thrombosis is another frequent manifestation of Covid-19 that contributes to poor outcomes. Vitamin K plays a crucial role in the activation of both pro- and anticlotting factors in the liver and the activation of extrahepatically synthesised protein S which seems to be important in local thrombosis prevention. However, the role of vitamin K extends beyond coagulation. Matrix Gla protein (MGP) is a vitamin K-dependent inhibitor of soft tissue calcification and elastic fibre degradation. Severe extrahepatic vitamin K insufficiency was recently demonstrated in Covid-19 patients, with high inactive MGP levels correlating with elastic fibre degradation rates. This suggests that insufficient vitamin K-dependent MGP activation leaves elastic fibres unprotected against SARS-CoV-2-induced proteolysis. In contrast to MGP, Covid-19 patients have normal levels of activated factor II, in line with previous observations that vitamin K is preferentially transported to the liver for activation of procoagulant factors. We therefore expect that vitamin K-dependent endothelial protein S activation is also compromised, which would be compatible with enhanced thrombogenicity. Taking these data together, we propose a mechanism of pneumonia-induced vitamin K depletion, leading to a decrease in activated MGP and protein S, aggravating pulmonary damage and coagulopathy, respectively. Intervention trials should be conducted to assess whether vitamin K administration plays a role in the prevention and treatment of severe Covid-19.
Asunto(s)
COVID-19/patología , Pulmón/fisiopatología , SARS-CoV-2 , Tromboembolia/prevención & control , Trombosis/prevención & control , Deficiencia de Vitamina K/metabolismo , Vitamina K/metabolismo , COVID-19/complicaciones , Proteínas de Unión al Calcio/metabolismo , Proteínas de la Matriz Extracelular/metabolismo , Humanos , Proteína S/metabolismo , Tromboembolia/etiología , Trombosis/etiología , Vitamina K/antagonistas & inhibidores , Deficiencia de Vitamina K/etiología , Proteína Gla de la MatrizRESUMEN
Covid-19, caused by SARS-CoV-2, has major world-wide health-related and socio-economic consequences. There are large disparities in the burden of Covid-19 with an apparent lower risk of poor outcomes in East Asians compared to populations in the West. A recent study suggested that Covid-19 leads to a severe extrahepatic vitamin K insufficiency, which could lead to impaired activation of extrahepatic proteins like endothelial anticoagulant protein S in the presence of normal hepatic procoagulant activity. This would be compatible with the enhanced thrombogenicity in severe Covid-19. The same study showed that vitamin K antagonists (VKA) that inhibit vitamin K recycling, had a greater impact on procoagulant activity than on the activation of extrahepatic vitamin K-dependent proteins during SARS-CoV-2 infections. A genetic polymorphism in the vitamin K epoxide reductase complex 1, VKORC1 -1639A, is particularly prevalent in East Asia and associates with low vitamin K recycling rates. Carriage of the allele may be regarded as bioequivalent to low-dose VKA use. We speculate that VKORC1 -1639A confers protection against thrombotic complications of Covid-19 and that differences in its allele frequency are partially responsible for the differences in Covid-19 severity between East and West.
Asunto(s)
COVID-19/genética , Vitamina K Epóxido Reductasas/genética , Américas/epidemiología , COVID-19/complicaciones , COVID-19/enzimología , Europa (Continente)/epidemiología , Asia Oriental/epidemiología , Frecuencia de los Genes , Humanos , Modelos Biológicos , Pandemias , Polimorfismo de Nucleótido Simple , SARS-CoV-2 , Índice de Severidad de la Enfermedad , Trombosis/etiología , Trombosis/genética , Trombosis/prevención & control , Vitamina K/antagonistas & inhibidores , Deficiencia de Vitamina K/etiologíaRESUMEN
Patients with intestinal fat malabsorption and urolithiasis are particularly at risk of acquiring fat-soluble vitamin deficiencies. The aim of the study was to evaluate the vitamin status and metabolic profile before and after the supplementation of fat-soluble vitamins A, D, E and K (ADEK) in 51 patients with fat malabsorption due to different intestinal diseases both with and without urolithiasis. Anthropometric, clinical, blood and 24-h urinary parameters and dietary intake were assessed at baseline and after ADEK supplementation for two weeks. At baseline, serum aspartate aminotransferase (AST) activity was higher in stone formers (SF; n = 10) than in non-stone formers (NSF; n = 41) but decreased significantly in SF patients after supplementation. Plasma vitamin D and E concentrations increased significantly and to a similar extent in both groups during intervention. While plasma vitamin D concentrations did not differ between the groups, vitamin E concentrations were significantly lower in the SF group than the NSF group before and after ADEK supplementation. Although vitamin D concentration increased significantly in both groups, urinary calcium excretion was not affected by ADEK supplementation. The decline in plasma AST activity in patients with urolithiasis might be attributed to the supplementation of ADEK. Patients with fat malabsorption may benefit from the supplementation of fat-soluble vitamins ADEK.
Asunto(s)
Síndromes de Malabsorción/sangre , Urolitiasis/sangre , Vitamina A/sangre , Vitamina D/sangre , Vitamina E/sangre , Vitamina K/sangre , Adulto , Anciano , Aspartato Aminotransferasas/sangre , Colesterol/sangre , Suplementos Dietéticos , Femenino , Humanos , Síndromes de Malabsorción/complicaciones , Síndromes de Malabsorción/terapia , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Triglicéridos/sangre , Urolitiasis/complicaciones , Urolitiasis/terapia , Vitamina A/administración & dosificación , Deficiencia de Vitamina A/sangre , Deficiencia de Vitamina A/etiología , Deficiencia de Vitamina A/terapia , Vitamina D/administración & dosificación , Deficiencia de Vitamina D/sangre , Deficiencia de Vitamina D/etiología , Deficiencia de Vitamina D/terapia , Vitamina E/administración & dosificación , Deficiencia de Vitamina E/sangre , Deficiencia de Vitamina E/etiología , Deficiencia de Vitamina E/terapia , Vitamina K/administración & dosificación , Deficiencia de Vitamina K/sangre , Deficiencia de Vitamina K/etiología , Deficiencia de Vitamina K/terapia , Vitaminas/administración & dosificación , Vitaminas/sangreRESUMEN
INTRODUCTION: End stage renal failure patients on hemodialysis have significant vascular calcification This is postulated to be related to sub-clinical vitamin K deficiency, which is prevalent in hemodialysis patients. Vitamin K deficiency result in the failure of the matrix GLA protein (MGP) to undergo carboxylation. MGP is a natural local inhibitor of vascular calcification and the lack of functional carboxylated MGP may contribute to increase vascular calcification. Vitamin K supplement should therefore correct this anomaly and decrease the rate or severity of vascular calcification in this population of patients on long-term maintenance hemodialysis. Our study seeks to evaluate the prevalence and the progression of vascular calcification in a cohort of maintenance hemodialysis patients. It will also evaluate the efficacy of vitamin K supplementation in reducing the progression of vascular calcification in this group of patients. METHODS: This will be a single-center randomized, prospective and open-label interventional clinical trial of end stage renal failure patients on hemodialysis. We aim to recruit 200 patients. Eligible patients will be randomized to either the standard care arm or active treatment arm. Active treatment arm patients will receive standard care plus supplementation with oral vitamin K2 isoform 360 mcg 3 times weekly for a total duration of 18 months. Primary outcome measured will be absolute difference in coronary artery calcification score at 18-month between control and intervention arms. Secondary outcomes will be to compare absolute difference in aortic valve calcification, percentage of patients with regression of coronary artery calcification of at least 10%, absolute difference in aortic and systemic arterial stiffness, mortality from any cause and major adverse cardiovascular over the same period. DISCUSSION: Evidence of successful regression or retardation of vascular calcification will support the conduct of larger and longer-term trials aimed at reducing cardiovascular disease mortality and major adverse cardiovascular events in this high-risk population using a safe and inexpensive strategy TRIAL REGISTRATION:: ClinicalTrials.gov NCT02870829. Registered on 17 August 2016 - Retrospectively registered, https://clinicaltrials.gov/ct2/show/NCT02870829National University Hospital's Institutional Review Board (2015/01000).
Asunto(s)
Diálisis Renal/efectos adversos , Calcificación Vascular/prevención & control , Vitamina K 2/administración & dosificación , Deficiencia de Vitamina K/tratamiento farmacológico , Adulto , Esquema de Medicación , Femenino , Humanos , Fallo Renal Crónico/terapia , Persona de Mediana Edad , Ensayos Clínicos Controlados Aleatorios como Asunto , Vitamina K 2/farmacología , Deficiencia de Vitamina K/etiologíaRESUMEN
Background: A low vitamin K status is common in patients on haemodialysis, and this is considered one of the reasons for the accelerated atherosclerosis in these patients. The vitamin is essential in activation of the protein Matrix Gla Protein (MGP), and the inactive form, dp-ucMGP, is used to measure vitamin K status. The purpose of this study was to investigate possible underlying causes of low vitamin K status, which could potentially be low intake, washout during dialysis or inhibited absorption capacity. Moreover, the aim was to investigate whether the biomarker dp-ucMGP is affected in these patients. Method: Vitamin K intake was assessed by a Food Frequency Questionnaire (FFQ) and absorption capacity by means of D-xylose testing. dp-ucMGP was measured in plasma before and after dialysis, and phylloquinine (vitamin K1) and dp-ucMGP were measured in the dialysate. Changes in dp-ucMGP were measured after 14 days of protein supplementation. Results: All patients had plasma dp-ucMGP above 750 pmol/L, and a low intake of vitamin K. The absorption capacity was normal. The difference in dp-ucMGP before and after dialysis was -1022 pmol/L (p < 0.001). Vitamin K1 was not present in the dialysate but dp-ucMGP was at a high concentration. The change in dp-ucMGP before and after protein supplementation was -165 pmol/L (p = 0.06). Conclusion: All patients had vitamin K deficiency. The reason for the low vitamin K status is not due to removal of vitamin K during dialysis or decreased absorption but is plausibly due to a low intake of vitamin K in food. dp-ucMGP is washed out during dialysis, but not affected by protein intake to a clinically relevant degree.
Asunto(s)
Ingestión de Alimentos/fisiología , Conducta Alimentaria/fisiología , Fenómenos Fisiológicos de la Nutrición/fisiología , Diálisis Renal , Deficiencia de Vitamina K/etiología , Vitamina K/administración & dosificación , Anciano , Anciano de 80 o más Años , Biomarcadores/sangre , Proteínas de Unión al Calcio/sangre , Proteínas de la Matriz Extracelular/sangre , Femenino , Humanos , Masculino , Persona de Mediana Edad , Encuestas y Cuestionarios , Vitamina K/metabolismo , Deficiencia de Vitamina K/diagnóstico , Proteína Gla de la MatrizRESUMEN
We have previously reported that patients with severe motor and intellectual disabilities (SMID) have a high prevalence of vitamin K deficiency both in the liver and bone. Thus, vitamin K therapy for SMID patients should be considered. In the present study, we have studied the efficacy of nutritional therapy with vitamin K1 for improving their vitamin K status and bone metabolism markers in patients with SMID. During the 3-mo period, 19 patients under enteral feeding received vitamin K1 treatment, the dose of which was determined to meet each subject's energy requirement. Biomarkers of vitamin K insufficiency; protein induced by vitamin K absence or antagonist-II (PIVKA-II), undercarboxylated osteocalcin (ucOC), intact osteocalcin (intact OC) and bone turnover markers (tartrate-resistant acid phosphatase-5b: TRACP-5b and bone alkaline phosphatase: BAP) were measured at baseline and post treatment. The ucOC/OC ratio was calculated as a more sensitive index than ucOC for vitamin K status in the bone. After treatment, the median vitamin K intake increased from 66 to 183 µg/d, and serum levels of PIVKA-II and ucOC/OC ratio were significantly decreased. Decrements of serum ucOC level and ucOC/OC ratio were significantly associated with vitamin K intake, indicating that both markers well reflect the dose-dependent vitamin K effects. Serum levels of BAP and TRACP-5b were significantly increased after vitamin K1 therapy. Nutritional therapy with vitamin K1 effectively improved the markers for vitamin K status and bone turnover, and was considered to be a good candidate for treatment in SMID patients.
Asunto(s)
Remodelación Ósea , Huesos/metabolismo , Discapacidad Intelectual/complicaciones , Trastornos Motores/complicaciones , Vitamina K 1/uso terapéutico , Deficiencia de Vitamina K/tratamiento farmacológico , Adulto , Fosfatasa Alcalina/sangre , Biomarcadores/sangre , Personas con Discapacidad , Femenino , Humanos , Discapacidad Intelectual/sangre , Persona de Mediana Edad , Trastornos Motores/sangre , Terapia Nutricional , Necesidades Nutricionales , Estado Nutricional , Osteocalcina/sangre , Precursores de Proteínas/sangre , Protrombina , Índice de Severidad de la Enfermedad , Fosfatasa Ácida Tartratorresistente/sangre , Resultado del Tratamiento , Vitamina K 1/sangre , Deficiencia de Vitamina K/sangre , Deficiencia de Vitamina K/etiología , Adulto JovenRESUMEN
An 8-month-old child under tuberculosis treatment presented with multiple ecchymotic lesions. A severe coagulopathy was evidenced compatible with vitamin K deficiency [II (3%), VII (2%), IX (3%) and X (1%)]. It was reversed with vitamin K and plasma administration. Rifampicin-induced vitamin K deficiency is very rare, reported only once before, possibly related to an inhibition of vitamin K cycle.
Asunto(s)
Antibióticos Antituberculosos/efectos adversos , Trastornos de la Coagulación Sanguínea/inducido químicamente , Trastornos de la Coagulación Sanguínea/diagnóstico , Rifampin/efectos adversos , Deficiencia de Vitamina K/complicaciones , Trastornos de la Coagulación Sanguínea/tratamiento farmacológico , Trastornos de la Coagulación Sanguínea/terapia , Niño , Humanos , Lactante , Masculino , Plasma , Resultado del Tratamiento , Tuberculosis/tratamiento farmacológico , Vitamina K/administración & dosificación , Deficiencia de Vitamina K/etiologíaRESUMEN
Vitamin K is a cofactor of γ-glutamyl carboxylase, which plays an important role in the activation of γ-carboxyglutamate (gla)-containing proteins that negatively regulate calcification. Thus, vitamin K status might be associated with osteoarthritis (OA), in which cartilage calcification plays a role in the pathogenesis of the disease. This review collates the evidence on the relationship between vitamin K status (circulating or dietary intake level of vitamin K, or circulating uncarboxylated gla proteins) and OA from human observational studies and clinical trial, to examine its potential as an agent in preventing OA. The current literature generally agrees that a sufficient level of vitamin K is associated with a lower risk of OA and pathological joint features. However, evidence from clinical trials is limited. Mechanistic study shows that vitamin K activates matrix gla proteins that inhibit bone morphogenetic protein-mediated cartilage calcification. Gla-rich proteins also inhibit inflammatory cascade in monocytic cell lines, but this function might be independent of vitamin K-carboxylation. Although the current data are insufficient to establish the optimal dose of vitamin K to prevent OA, ensuring sufficient dietary intake seems to protect the elderly from OA.
Asunto(s)
Osteoartritis/epidemiología , Osteoartritis/etiología , Vitamina K/metabolismo , Biomarcadores , Calcio/metabolismo , Suplementos Dietéticos , Susceptibilidad a Enfermedades , Humanos , Vigilancia de la Población , Deficiencia de Vitamina K/complicaciones , Deficiencia de Vitamina K/etiología , Deficiencia de Vitamina K/metabolismoRESUMEN
Infection with Helicobacter pylori causes chronic inflammation and is a risk factor for gastric cancer. Antibiotic treatment or increased dietary folate prevents gastric carcinogenesis in male INS-GAS mice. To determine potential synergistic effects, H. pylori-infected male INS-GAS mice were fed an amino acid defined (AAD) diet with increased folate and were treated with antibiotics after 18 weeks of H. pylori infection. Antibiotic therapy decreased gastric pathology, but dietary folate had no effect. However, the combination of antibiotics and the AAD diet induced anemia, gastric hemorrhage, and mortality. Clinical presentation suggested hypovitaminosis K potentially caused by dietary deficiency and dysbiosis. Based on current dietary guidelines, the AAD diet was deficient in vitamin K. Phylloquinone administered subcutaneously and via a reformulated diet led to clinical improvement with no subsequent mortalities and increased hepatic vitamin K levels. We characterized the microbiome and menaquinone profiles of antibiotic-treated and antibiotic-free mice. Antibiotic treatment decreased the abundance of menaquinone producers within orders Bacteroidales and Verrucomicrobiales. PICRUSt predicted decreases in canonical menaquinone biosynthesis genes, menA and menD. Reduction of menA from Akkermansia muciniphila, Bacteroides uniformis, and Muribaculum intestinale were confirmed in antibiotic-treated mice. The fecal menaquinone profile of antibiotic-treated mice had reduced MK5 and MK6 and increased MK7 and MK11 compared to antibiotic-free mice. Loss of menaquinone-producing microbes due to antibiotics altered the enteric production of vitamin K. This study highlights the role of diet and the microbiome in maintaining vitamin K homeostasis.
Asunto(s)
Antibacterianos/uso terapéutico , Disbiosis/etiología , Alimentos Formulados/efectos adversos , Hemorragia Gastrointestinal/etiología , Microbioma Gastrointestinal , Infecciones por Helicobacter/tratamiento farmacológico , Deficiencia de Vitamina K/etiología , Aminoácidos/administración & dosificación , Anemia/dietoterapia , Anemia/etiología , Animales , Antibacterianos/efectos adversos , Bacterias/efectos de los fármacos , Bacterias/genética , Bacterias/metabolismo , Dieta , Suplementos Dietéticos , Ácido Fólico/administración & dosificación , Ácido Fólico/biosíntesis , Ácido Fólico/genética , Microbioma Gastrointestinal/efectos de los fármacos , Infecciones por Helicobacter/microbiología , Helicobacter pylori/efectos de los fármacos , Hígado/metabolismo , Masculino , Ratones , Vitamina K 1/administración & dosificación , Vitamina K 1/metabolismo , Vitamina K 2/metabolismoRESUMEN
OBJECTIVE: To compare the prevalence of vitamin K deficiency after intramuscular vitamin K or no treatment in neonates with sepsis on prolonged (>7 days) antibiotic therapy. STUDY DESIGN: Open label randomized controlled trial. SETTING: Level 3 Neonatal Intensive Care Unit (NICU). PARTICIPANTS: Neonates with first episode of sepsis on antibiotics for ≥7 days were included. Neonates with clinical bleeding, vitamin K prior to start of antibiotic therapy (except the birth dose), cholestasis or prenatally diagnosed bleeding disorder were excluded. INTERVENTIONS: Randomized to receive 1 mg vitamin K (n=41) or no vitamin K (n=39) on the 7th day of antibiotic therapy. MAIN OUTCOME MEASURES: Vitamin K deficiency defined as Protein Induced by Vitamin K Absence (PIVKA-II) >>2 ng/mL after 7 ± 2 days of enrolment. RESULTS: The prevalence of vitamin K deficiency was 100% (n=80) at enrolment and it remained 100% even after 7 ± 2 days of enrolment in both the groups. CONCLUSIONS: Neonates receiving prolonged antibiotics have universal biochemical vitamin K deficiency despite vitamin K administration on 7th day of antibiotic therapy.
Asunto(s)
Antibacterianos/uso terapéutico , Cuidado Intensivo Neonatal/métodos , Síndrome de Lemierre/tratamiento farmacológico , Deficiencia de Vitamina K/prevención & control , Vitamina K/uso terapéutico , Vitaminas/uso terapéutico , Femenino , Estudios de Seguimiento , Humanos , Recién Nacido , Inyecciones Intramusculares , Unidades de Cuidado Intensivo Neonatal , Síndrome de Lemierre/complicaciones , Masculino , Prevalencia , Resultado del Tratamiento , Deficiencia de Vitamina K/diagnóstico , Deficiencia de Vitamina K/epidemiología , Deficiencia de Vitamina K/etiologíaRESUMEN
Cystic fibrosis (CF) is an inherited genetic disorder with multiorgan involvement. Gastrointestinal tract dysfunction leads to fat and fat-soluble vitamins (A,D,E,K) malabsorption and deficiency of these vitamins. Subclinical vitamin K (VK) deficiency seems to be a common problem in CF patients. However, despite the rest of fat-soluble vitamins being routinely supplemented, this is not a universal clinical practice for VK. Inefficient levels of VK may have significant effects on blood coagulation and bone formation. There are also some data indicating that VK may play a key role on regulation of inflammation. Supplementing CF patients with VK seems rational, but the appropriate dosing regimens are still a matter of debate. This review will try to delineate the problem and communicate the latest opinions on this controversial issue.
Asunto(s)
Fibrosis Quística/complicaciones , Deficiencia de Vitamina K/etiología , Vitamina K/fisiología , Coagulación Sanguínea , Humanos , OsteogénesisRESUMEN
BACKGROUND: Vitamin K deficiency results in serious coagulation dysfunction, but hemorrhagic shock is rare. Herein, we describe a case of vitamin K deficiency and abnormality in the path of the intercostal artery, the combination of which led to hemorrhagic shock. CASE PRESENTATION: An 83-year-old woman was hospitalized for suspected gallstones. She developed septic shock after 4 days of hospitalization. We considered cholecystitis or cholangitis and performed abdominal ultrasonography, which revealed gallbladder enlargement, biliary sludge, and hyperplasia of the bile duct wall. Antibiotic treatment with sulbactam/ampicillin (SBT/ABPC) was initiated on day four, and percutaneous transhepatic gallbladder drainage (PTGBD) was performed on day five. The treatment was successful, but the patient developed bilateral pleural effusion because of hypoalbuminemia. We performed drainage for bilateral pleural effusion on days 13 and 17. The patient developed hypotension on day 18; blood tests showed anemia and severe coagulation dysfunction but a normal platelet count. We suspected vitamin K deficiency-induced coagulation dysfunction because of previous antibiotic treatment and restricted diet, and it led to hemorrhagic shock. Massive right hemothorax was observed by computed tomography, and urgent interventional radiology was performed. We observed no injury to the intercostal artery truncus but confirmed an abnormality in the course of the intercostal artery; therefore, we inferred that the cause of hemothorax in this case was injury to a small vessel, not truncus because of the abnormality. Because of the likelihood of rebleeding, we performed coil embolization from the seventh to the ninth intercostal artery. Because we confirmed vitamin K deficiency-induced coagulation dysfunction, we referred to the concentration of protein induced by vitamin K absence/antagonist-II (PIVKA-II), and it was found to increase by 23,000. CONCLUSIONS: A combination of vitamin K deficiency and abnormality in the course of the intercostal artery led to hemorrhagic shock. When using certain antibiotics and restricting diet, it is important to measure coagulation function, even if the platelet count is normal. Further, when thoracentesis is performed, abnormalities in the course of the intercostal artery should be identified. Thoracentesis with ultrasound may prevent hemothorax.
Asunto(s)
Arterias/anomalías , Costillas/irrigación sanguínea , Choque Hemorrágico/etiología , Toracocentesis/efectos adversos , Deficiencia de Vitamina K/complicaciones , Anciano de 80 o más Años , Ampicilina/efectos adversos , Ampicilina/uso terapéutico , Antibacterianos/efectos adversos , Antibacterianos/uso terapéutico , Colecistitis/terapia , Dieta con Restricción de Grasas/efectos adversos , Drenaje , Femenino , Cálculos Biliares/terapia , Humanos , Derrame Pleural/cirugía , Sulbactam/efectos adversos , Sulbactam/uso terapéutico , Deficiencia de Vitamina K/etiologíaRESUMEN
Patients with primary biliary cholangitis (PBC) are at risk for various harmful consequences of chronic cholestasis. These include fat-soluble vitamin deficiency, even in the setting of macronutrient sufficiency, as well as metabolic bone disease, including osteoporosis with fractures. Hyperlipidemia is often present and less commonly associated with risk of cardiovascular event; however, the long-term effect of new emerging therapies for PBC remains to be determined. Patients with PBC also have infrequent but notable risk of portal hypertension despite early-stage disease. This review discusses the background, evaluation, and practical management of these complications of chronic cholestasis.
Asunto(s)
Avitaminosis/diagnóstico , Carcinoma Hepatocelular/diagnóstico , Hiperlipidemias/diagnóstico , Hipertensión Portal/diagnóstico , Hipertensión Portal/terapia , Cirrosis Hepática Biliar/terapia , Neoplasias Hepáticas/diagnóstico , Osteoporosis/diagnóstico , Absorciometría de Fotón , Avitaminosis/etiología , Avitaminosis/terapia , Conservadores de la Densidad Ósea/uso terapéutico , Enfermedades Óseas Metabólicas/diagnóstico , Enfermedades Óseas Metabólicas/tratamiento farmacológico , Enfermedades Óseas Metabólicas/etiología , Carcinoma Hepatocelular/etiología , Carcinoma Hepatocelular/terapia , Colestasis/complicaciones , Colestasis/terapia , Dieta Saludable , Detección Precoz del Cáncer , Várices Esofágicas y Gástricas/diagnóstico , Várices Esofágicas y Gástricas/etiología , Várices Esofágicas y Gástricas/terapia , Ejercicio Físico , Ácidos Fíbricos/uso terapéutico , Hemorragia Gastrointestinal/diagnóstico , Hemorragia Gastrointestinal/etiología , Hemorragia Gastrointestinal/terapia , Humanos , Inhibidores de Hidroximetilglutaril-CoA Reductasas/uso terapéutico , Hiperlipidemias/etiología , Hiperlipidemias/terapia , Hipertensión Portal/etiología , Cirrosis Hepática Biliar/complicaciones , Neoplasias Hepáticas/etiología , Neoplasias Hepáticas/terapia , Tamizaje Masivo , Osteoporosis/tratamiento farmacológico , Osteoporosis/etiología , Fracturas Osteoporóticas/prevención & control , Deficiencia de Vitamina A/diagnóstico , Deficiencia de Vitamina A/etiología , Deficiencia de Vitamina A/terapia , Deficiencia de Vitamina D/diagnóstico , Deficiencia de Vitamina D/etiología , Deficiencia de Vitamina D/terapia , Deficiencia de Vitamina E/diagnóstico , Deficiencia de Vitamina E/etiología , Deficiencia de Vitamina E/terapia , Deficiencia de Vitamina K/diagnóstico , Deficiencia de Vitamina K/etiología , Deficiencia de Vitamina K/terapiaRESUMEN
Previous studies have shown that α-tocopherol intake lowers phylloquinone (PK) concentration in some extrahepatic tissues in rats. The study's aim was to clarify the effect of α-tocopherol intake on vitamin K concentration in bone, as well as the physiological action of vitamin K. Male Wistar rats were divided into 4 groups. Over a 3-mo period, the K-free group was fed a vitamin K-free diet with 50 mg RRR-α-tocopherol/kg, the E-free group was fed a diet containing 0.75 mg PK/kg without vitamin E, the control group was fed a diet containing 0.75 mg PK/kg with 50 mg RRR-α-tocopherol/kg, and the E-excess group was fed a diet containing 0.75 mg PK/kg with 500 mg RRR-α-tocopherol/kg. PK concentration in the liver was higher in E-excess rats than in E-free rats, was lower in the tibias of control rats than in those of E-free rats, and was lower in E-excess rats than in control rats. Menaquinone-4 (MK-4) concentration in the liver was higher in E-excess rats than in E-free and control rats. However, MK-4 concentrations in the tibias of E-free, control, and E-excess rats were almost the same. Blood coagulation activity was lower in K-free rats than in the other rats but was not affected by the level of α-tocopherol intake. Additionally, dietary intake of PK and α-tocopherol did not affect uncarboxylated-osteocalcin concentration in the serum, femur density, or expression of the genes related to bone resorption and formation in the femur. These results suggest that α-tocopherol intake decreases PK concentration in bone but does not affect bone metabolism in rats.
Asunto(s)
Desarrollo Óseo , Huesos/metabolismo , Metabolismo Energético , Regulación del Desarrollo de la Expresión Génica , Vitamina K 1/antagonistas & inhibidores , Deficiencia de Vitamina K/etiología , alfa-Tocoferol/envenenamiento , Animales , Biomarcadores/sangre , Biomarcadores/metabolismo , Densidad Ósea , Huesos/química , Dieta/efectos adversos , Suplementos Dietéticos/envenenamiento , Hígado/metabolismo , Masculino , Especificidad de Órganos , Osteocalcina/sangre , Ratas Wistar , Organismos Libres de Patógenos Específicos , Tibia , Vitamina K 1/metabolismo , Vitamina K 1/uso terapéutico , Vitamina K 2/análogos & derivados , Vitamina K 2/metabolismo , Deficiencia de Vitamina K/metabolismo , Deficiencia de Vitamina K/fisiopatología , Deficiencia de Vitamina K/terapia , Sangrado por Deficiencia de Vitamina K/etiología , Sangrado por Deficiencia de Vitamina K/prevención & control , Aumento de PesoAsunto(s)
Apolipoproteínas E/genética , Fibrosis Quística , Deficiencia de Vitamina K , Vitamina K , Adolescente , Fibrosis Quística/genética , Fibrosis Quística/metabolismo , Fibrosis Quística/terapia , Suplementos Dietéticos , Femenino , Humanos , Masculino , Pruebas de Farmacogenómica , Polimorfismo Genético , Resultado del Tratamiento , Vitamina K/administración & dosificación , Vitamina K/farmacocinética , Deficiencia de Vitamina K/etiología , Deficiencia de Vitamina K/prevención & control , Vitaminas/administración & dosificación , Vitaminas/farmacocinética , Adulto JovenRESUMEN
BACKGROUND: In children diagnosed with celiac disease, fat soluble vitamin levels were aimed to be evaluated and it was intended to determine whether fat soluble vitamin levels were needed to be assessed routinely in these patients during diagnosis. METHODS: Between May 2015-May 2016, diagnosis symptoms of celiac patients (CD) in newly diagnosed pediatric group were questioned, fat soluble vitamin levels simultaneous with intestinal biopsies were evaluated. Vitamin levels were compared with those of healthy control group. RESULTS: A total of 52 patients involving 27 female (51.9%), 25 male (48.1%); and a total of 50 healthy control group including 25 female (50%), 25 male (50%) were evaluated. The average age of patients was 9 ± 4.3 years, and their average weight was determined as 16.2 ± 6.3 kg. Growth retardation was the most frequent symptom in our patients (61.5%). Abdominal pain (51.9%) and diarrhea (11.5%) are among the other most commonly seen symptoms. In the histological examination of patients, Marsh 3B n = 23 (45.1%) was mostly established. Vitamin A and vitamin D levels of patients were determined significantly lower compared to those of control group. Vitamin A and vitamin D deficiencies were identified significantly higher compared to those of healthy control group. Vitamin D insufficiency was observed in 48 patients (92.3%) and vitamin D deficiency was determined in 32 (61.5%) out of 48. Vitamin A deficiency was established in 17 (32.7%) patients. Vitamin E and vitamin K1 deficiency were determined in no patients. In the healthy control group, vitamin D deficiency was seen in 2 (4%) patients, vitamin D insufficiency was determined in 9 (18%) patients. Other vitamin levels were identified at normal levels in the healthy group. CONCLUSIONS: In newly diagnosed children with CD, a significant lowness was established in vitamin D and A. The evaluation of vitamin A and D levels will be helpful in the course of diagnosis in these patients.
Asunto(s)
Avitaminosis/etiología , Enfermedad Celíaca/complicaciones , Enfermedad Celíaca/diagnóstico , Adolescente , Estudios de Casos y Controles , Enfermedad Celíaca/sangre , Enfermedad Celíaca/patología , Niño , Preescolar , Femenino , Humanos , Lactante , Recién Nacido , Intestinos/patología , Masculino , Deficiencia de Vitamina A/etiología , Deficiencia de Vitamina D/etiología , Deficiencia de Vitamina E/etiología , Vitamina K 1/sangre , Deficiencia de Vitamina K/etiologíaRESUMEN
Introducción. La deficiencia de vitamina K es prevalente en pacientes con fibrosis quística (FQ) aun con aporte suplementario. Se desconocen factores de riesgo fiables para determinar su ocurrencia. Nuestro objetivo fue evaluar la prevalencia de deficiencia de vitamina K y factores asociados en los pacientes con FQ que no recibían aporte suplementario. Métodos. Se determinaron protrombina inducida por ausencia de vitamina K (PIVKA-II) y osteocalcina infracarboxilada (OCic). Se evaluó el estado clínico y su relación con la deficiencia de vitamina K. El análisis estadístico incluyó prueba de Mann-Whitney, ANOVA o Kruskal-Wallis, prueba χ² o prueba de Fisher-Freeman-Halton y regresión logística múltiple lineal y escalonada hacia adelante. Resultados. Se incluyeron 79 pacientes con FQ de entre 0,4-25,3 años. Se observaron valores anómalos de PIVKA-II y OCic en 56 (70,9%) y 45 (57,0%) pacientes. Los pacientes con PIVKA-II elevada eran significativamente mayores (p = 0,0184) y tenían puntajes Z de peso corporal (p= 0,0297) inferiores a los pacientes que tenían concentraciones normales. No se hallaron diferencias entre los pacientes con OCic normal o patológica. Se notificaron valores anómalos de PIVKA-II y OCic más frecuentemente en pacientes con dos mutaciones graves en el gen CFTR y con un estado nutricional malo/deficiente. Los análisis de regresión múltiple lineal y de regresión múltiple escalonada hacia adelante no revelaron factores predictivos sólidos para determinar la deficiencia de vitamina K. Conclusión. La deficiencia de vitamina K es altamente prevalente durante la evolución natural de la fibrosis quística. No se hallaron determinantes clínicos fiables para precisar su ocurrencia.
Introduction. Vitamin K deficiency is highly prevalent in cystic fibrosis (CF) patients despite supplementation. Moreover, no reliable risk factors for its occurrence are known. The aim was to assess the prevalence of vitamin K deficiency and associated factors in non-supplemented CF patients. Methods. Prothrombin concentration induced by vitamin K absence (PIVKA-II) and the undercarboxylated osteocalcin percentage (u-OC) were determined. In all patients clinical status was assessed and its relation to vitamin K deficiency determined. The following tests were used for statistical analysis: Mann-Whitney test, ANOVA test or the Kruskal Wallis test, the chi-squared test or the Fisher-Freeman-Halton test, and multiple linear and multiple forward stepwise logistic regression analysis. Results. The study group comprised 79 CF patients aged 0.4-25.3 years. PIVKA-II and u-OC were abnormal in 56 (70.9%) and 45 (57.0%) patients. Patients with elevated PIVKA-II were significantly older (p= 0.0184) and had lower Z-score values for body weight (p= 0.0297) than those with normal concentrations. Patients with normal or pathological u-OC percentage did not differ. Abnormal PIVKA-II and u-OC were reported more frequently in subjects with two severe CFTR mutations and with worse/poor nutritional status. Multiple linear and forward stepwise regression analyses did not reveal strong predictive factors of vitamin K deficiency. Conclusion. Vitamin K deficiency is highly prevalent in the natural course of cystic fibrosis. There are no reliable clinical determinants of its occurrence.